

04-05-04



Express Mail No. EV322529932US
Attorney Docket No. ARR002
Client/Matter No. 80248.0024.000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eli Wallace

Serial No. 10/642,440

Filed: August 14, 2003

For: QUINAZOLINE ANALOGS AS RECEPTOR
TYROSINE KINASE INHIBITORS

Group Art Unit: 1614

Examiner: Not yet accorded

CERTIFICATE OF MAILING BY EXPRESS MAIL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The undersigned hereby certifies that the attached:

1. First Supplemental Information Disclosure Statement;
2. Form PTO/SB/08A, with copies of 2 non-patent literature references;
3. Certificate of Mailing; and
4. Return card


relating to the above application, were deposited as "Express Mail" Mailing Label No. EV322529932US with the United States Postal Service, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 2, 2004
Date


Mailer

April 2, 2004
Date


Sarah J. Smith, Reg. No. 41,226
HOGAN & HARTSON LLP
One Tabor Center
1200 17th Street, Suite 1500
Denver, Colorado 80202
(720) 406-5385 Tel
(720) 406-5301 Fax



Express Mail No. EV322529932US
Attorney Docket No. ARR002
Client/Matter No. 80248.0024.000

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eli Wallace, et al.

Serial No. 10/642,440

Filed: August 14, 2003

For: QUINAZOLINE ANALOGS AS RECEPTOR
TYROSINE KINASE INHIBITORS

Group Art Unit: 1614

Examiner: Not yet accorded

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Applicant hereby submits for filing under 37 CFR 1.97 a disclosure statement. In submitting these references, no representation is made or implied that the references are or are not material to the examination of this application. The patents, publications or other information of which Applicant is presently aware are listed in Form PTO/SB/08A submitted herewith and copies of non-patent literature are attached hereto.

No fee is believed due for this submittal. However, any fee deficiency associated with this submittal may be charged to Deposit Account No. 50-1123.

Respectfully submitted,

April 2, 2004
Date

Sarah J. Smith
Sarah J. Smith, Reg. No. 41,226
HOGAN & HARTSON LLP
One Tabor Center
1200 17th Street, Suite 1500
Denver, Colorado 80202
(720) 406-5385 Tel
(720) 406-53401 Fax



PTO/SB/08a(08/03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/642,440
				Filing Date	August 14, 2003
				First Named Inventor	Eli Wallace
				Art Unit	1614
				Examiner Name	Not yet accorded
Sheet	1	of		Attorney Docket No.	ARR002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ²
	1	DAVID W. RUSNAK, et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>in Vitro</i> and <i>in Vivo</i> , <i>Molecular Cancer Therapeutics</i> , 2001, Vol. 1 (December) pp. 85-94	
	2	DAVID W. RUSNAK, et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, <i>Cancer Research</i> , Vol. 61, pp. 7196-7203, October 1, 2001	

EXAMINER SIGNATURE		DATE CONSIDERED	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.